Preimplantation   genetic  testing   for    monogenic disorders (PGT-M) and   preimplantation      genetic testing for aneuploidy (PGT-A) are  both techniques used during in vitro fertilization (IVF) to   assess the genetic  health  of  embryos.   PGT-M   focuses   on screening embryos for single-gene disorders,  such as cystic fibrosis, sickle cell anemia, or Huntington's disease, ensuring  only    embryos   free   of    these conditions are selected. PGT-A, on the  other   hand, screens for chromosomal abnormalities like  trisomy 21  (Down syndrome)  or  trisomy  18,  assessing the number of chromosomes in the embryo.  Both  tests involve   an  embryo    biopsy   followed  by  genetic analysis. PGT-A helps increase   the  likelihood  of a successful pregnancy by   selecting  embryos   with the correct   number   of   chromosomes.   PGT-M is crucial for families with a  known  history of  genetic disorders.   Together,   these  tests    enhance     IVF outcomes by selecting    healthier     embryos      for implantation.